Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) CEO Sells 56,000 Shares of Stock

TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein sold 56,000 shares of TransMedics Group stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $115.63, for a total transaction of $6,475,280.00. Following the completion of the sale, the chief executive officer now owns 74,087 shares in the company, valued at approximately $8,566,679.81. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

TransMedics Group Trading Up 2.9 %

NASDAQ:TMDX traded up $3.55 on Friday, reaching $127.99. The company’s stock had a trading volume of 1,543,089 shares, compared to its average volume of 765,449. TransMedics Group, Inc. has a 12-month low of $36.42 and a 12-month high of $129.66. The stock has a 50 day moving average price of $85.54 and a 200 day moving average price of $76.85. The firm has a market cap of $4.19 billion, a price-to-earnings ratio of -376.44 and a beta of 1.87. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.40. The business had revenue of $96.90 million for the quarter, compared to the consensus estimate of $83.78 million. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 8.29%. The business’s revenue was up 132.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.08) EPS. On average, equities analysts anticipate that TransMedics Group, Inc. will post -0.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on TMDX. Oppenheimer increased their target price on TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a report on Wednesday. TD Cowen upped their target price on shares of TransMedics Group from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday. Piper Sandler restated an “overweight” rating and set a $120.00 target price (up from $95.00) on shares of TransMedics Group in a report on Wednesday. Morgan Stanley increased their price target on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, February 28th. Finally, Canaccord Genuity Group boosted their price objective on TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a research note on Wednesday. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $119.00.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TMDX. Venturi Wealth Management LLC acquired a new position in TransMedics Group during the 1st quarter worth about $30,000. Fidelis Capital Partners LLC purchased a new stake in TransMedics Group during the first quarter worth about $35,000. Cutler Group LLC CA grew its holdings in shares of TransMedics Group by 600.0% in the third quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock valued at $38,000 after purchasing an additional 600 shares in the last quarter. RiverPark Advisors LLC purchased a new stake in TransMedics Group during the 3rd quarter worth approximately $60,000. Finally, First Horizon Advisors Inc. lifted its holdings in TransMedics Group by 26.8% during the 4th quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock worth $83,000 after buying an additional 222 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.